English فارسی

NTBF CEO: Iran among countries with technology to treat brain, breast cancers




Tehran, Nov 29, IRNA – Iran developed the technology to produce vaccines for treating brain and breast cancers thanks to efforts by domestic researchers and experts, said the managing director of an Iranian new technology-based firm (NTBF).

Norouz Dalirezh, whose institute has been operating in the field of producing vaccines for brain and breast cancer since two years ago, told IRNA on Wednesday that this was achieved after 15 years of research and development.

Commenting on the treatment procedure used by his company for brain cancer, he said first a sample of the tumor, taken during a surgery, is handed over to the firm, and then, based on the type of the tumor and blood sample, the company’s experts develop a vaccine and inject it to the patient.

Dalirezh noted that since the vaccine for brain cancer has foreign counterparts, the same method is used in certain other countries.

In this method, he added, a different dosage of vaccine is produced for each patient based on the results of his/her blood test and tumor sample.

“The vaccine for treating brain cancer has been used in Iran for two years. The Iranian Ministry of Health and Medical Education has allocated the budget for the project of producing the vaccine.”

Commenting on treating breast cancer using the same technique, he said the preliminary stages for treating this type of cancer through giving such vaccines have also been completed and currently the ground is prepared to this end in the country.

“We are waiting for the required credit to be extended and then begin the production and injection of the vaccine.”
He said this type of treatment is offered in a limited number of centers in the US, Germany and Australia.
“It can be claimed that Iran is currently among the world’s leading countries in this field.”

He put the price of the treatment in the US at $94,000 for each patient, noting that in Iran, it costs much less than this.


author: - Date: 11/29/2018